Magic mushrooms could be effective treatment for cocaine addiction, study shows – Image for illustrative purposes only (Image credits: Pixabay)
A single dose of psilocybin produced higher rates of cocaine abstinence than a placebo in a recent clinical trial. The study, published in JAMA Network Open, tracked 36 adults and found that those who received the psychedelic compound were more likely to stop using cocaine than those given diphenhydramine, an antihistamine used as the control. Researchers designed the trial to test whether one guided session could shift long-term behavior in people struggling with cocaine dependence. The results add to growing interest in psychedelic-assisted therapies, yet they also highlight how much remains unknown about lasting effects and broader application.
Trial Setup and Participant Details
The study enrolled adults with cocaine use disorder and randomly assigned them to one of two groups. Nineteen participants received a single dose of psilocybin under controlled conditions, while seventeen received the placebo. Both groups underwent similar preparation and monitoring to isolate the drug’s potential impact. The design allowed direct comparison of abstinence outcomes over the follow-up period.
Researchers chose diphenhydramine because it produces mild sedative effects without psychedelic properties. This choice helped maintain blinding and reduced the chance that expectations alone would drive results. All participants received behavioral support alongside the medication or placebo. The modest sample size reflects the early stage of this line of research.
Primary Outcomes and Group Comparison
Participants who received psilocybin showed greater success in maintaining abstinence from cocaine. The placebo group recorded lower rates of sustained avoidance. These differences emerged after the single dosing session and persisted through the study window. The findings suggest that psilocybin may influence the brain processes tied to craving and decision-making in ways standard treatments have not yet matched.
| Measure | Psilocybin Group (n=19) | Placebo Group (n=17) |
|---|---|---|
| Abstinence likelihood | Higher | Lower |
| Session format | Single guided dose | Single guided dose |
| Key limitation | Small sample, short follow-up | Small sample, short follow-up |
Remaining Questions and Study Limits
The trial leaves several important issues unresolved. No data yet show whether benefits continue beyond the initial months or whether repeated doses would strengthen results. Side effects, individual response variability, and the role of the therapeutic setting also require further examination. Larger studies will need to confirm these early signals before any clinical recommendations can form.
Researchers emphasized that psilocybin is not a standalone cure. The compound appears most effective when paired with counseling and structured support. Without those elements, outcomes could differ substantially. Ongoing work will test whether similar patterns appear in more diverse populations and longer time frames.
Path Forward for Psychedelic Research
This study contributes to a wider effort exploring psychedelics for substance-use disorders. Earlier trials have examined psilocybin for alcohol and tobacco dependence, creating a foundation for cocaine-specific investigations. Regulatory pathways remain cautious, and any future approval would depend on replicated findings across multiple sites. The current results nevertheless mark a measurable step toward new options for a condition that has proven difficult to treat.
Health systems continue to seek approaches that address both the neurological and behavioral sides of addiction. If subsequent research supports these initial observations, psilocybin-assisted therapy could eventually join existing medications and counseling programs. For now, the evidence points to a promising direction that merits careful, expanded study.